# Polycystic Ovary Syndrome

## Definition and Diagnosis

### Rotterdam Criteria (2003, Updated 2023)

The diagnosis of polycystic ovary syndrome (PCOS) requires the presence of two of three criteria after exclusion of other causes. The first criterion is oligo-anovulation, defined as menstrual cycles longer than 35 days, fewer than 8 cycles per year, or amenorrhea. The second is clinical and/or biochemical hyperandrogenism: clinical features include hirsutism (Ferriman-Gallwey score of 4-6 or greater), acne, and androgenic alopecia, while biochemical markers include elevated total or free testosterone, androstenedione, or DHEA-S. The third criterion is polycystic ovarian morphology on ultrasound, traditionally defined as 12 or more follicles of 2-9 mm per ovary or ovarian volume of 10 mL or greater on transvaginal ultrasound. With modern high-resolution ultrasonography, the threshold has been updated to 20 or more follicles per ovary. The 2023 guidelines also recognize an elevated anti-Mullerian hormone (AMH) above 3.4 ng/mL as a surrogate that can be used when ultrasound is unavailable or impractical. Importantly, not all three features need be present.

### Phenotypes

| Phenotype | Hyperandrogenism | Oligo-anovulation | Polycystic Morphology | Metabolic Risk | Prevalence |
|---|---|---|---|---|---|
| A (Classic, full-blown) | Yes | Yes | Yes | Highest | Most common |
| B (Classic) | Yes | Yes | No | High | Common |
| C (Ovulatory PCOS) | Yes | No (regular cycles) | Yes | Moderate | Less common |
| D (Non-hyperandrogenic) | No | Yes | Yes | Mildest | Least common; debated |

Four phenotypic presentations are recognized. Phenotype A (classic, full-blown) includes all three features: hyperandrogenism, oligo-anovulation, and polycystic morphology. Phenotype B (classic) includes hyperandrogenism and oligo-anovulation without polycystic morphology. Phenotype C (ovulatory PCOS) includes hyperandrogenism and polycystic morphology with regular cycles. Phenotype D (non-hyperandrogenic) includes oligo-anovulation and polycystic morphology without hyperandrogenism; this is the mildest form, and some debate exists about whether it represents true PCOS.

### Epidemiology

PCOS affects 6-13% of reproductive-age women depending on diagnostic criteria and population, making it the most common endocrine disorder in women of reproductive age and the most common cause of anovulatory infertility. Its significance extends well beyond reproductive health, carrying major metabolic and cardiovascular implications.

## Pathophysiology

### Neuroendocrine

The neuroendocrine derangement in PCOS involves increased GnRH pulse frequency, which preferentially drives LH secretion over FSH. The resulting elevated LH:FSH ratio (greater than 2:1 in many patients, though not diagnostic) stimulates excessive theca cell androgen production. The relative FSH deficiency impairs follicular maturation, leading to anovulation and the accumulation of multiple arrested antral follicles, producing the characteristic "polycystic" appearance on ultrasound.

### Ovarian

At the ovarian level, theca cell hyperfunction produces excessive androgens (testosterone, androstenedione) driven by LH stimulation and intrinsic enzyme overactivity, particularly CYP17 dysregulation. Granulosa cell dysfunction includes impaired aromatase activity (reducing conversion of androgens to estradiol) and elevated AMH production, which reflects the expanded follicle pool and is characteristically 2-3 times elevated in PCOS.

### Insulin Resistance and Hyperinsulinemia

Insulin resistance is present in 50-80% of PCOS patients, including both obese and lean women, making it a central pathogenic feature rather than merely a consequence of associated obesity. The mechanism involves a post-receptor signaling defect with serine phosphorylation of insulin receptor substrate-1. The resulting hyperinsulinemia exerts three crucial effects: it directly stimulates theca cell androgen production via insulin and IGF-1 receptors, decreases hepatic SHBG production (thereby increasing free testosterone), and augments LH-stimulated androgen synthesis. In many patients, insulin resistance functions as a primary driver of the PCOS phenotype.

### Adipose Tissue and Inflammation

Visceral adiposity produces inflammatory cytokines (TNF-alpha, IL-6) and adipokines (leptin, resistin) that worsen insulin resistance. Chronic low-grade inflammation, reflected by elevated CRP and white blood cell count, is characteristic. Adipose aromatase converts androgens to estrone (not estradiol), creating chronic estrogen exposure without the counterbalancing progesterone that normally follows ovulation, thereby increasing the risk of endometrial hyperplasia.

<image>A pathophysiology diagram of PCOS showing the interconnected hormonal and metabolic derangements. Central element: the ovary with arrested antral follicles. Inputs to the ovary: (1) From hypothalamus/pituitary: increased GnRH pulsatility → elevated LH:FSH ratio → LH drives theca cell androgen production while relative FSH deficiency causes follicular arrest. (2) From pancreas: hyperinsulinemia arrows stimulating theca cell androgens directly and suppressing hepatic SHBG. (3) From adipose tissue: increased aromatase converting androgens to estrone, plus inflammatory cytokines worsening insulin resistance. Outputs from ovary: elevated androgens → hirsutism, acne, alopecia, anovulation. Show a feedback loop: anovulation → no progesterone → chronic estrogen → endometrial hyperplasia risk. Include metabolic consequences: insulin resistance → glucose intolerance → type 2 diabetes, dyslipidemia, NAFLD. Use interconnected pathway diagram with arrows showing cause-effect relationships.</image>

## Evaluation

### Exclude Other Diagnoses

Before establishing a PCOS diagnosis, several conditions must be excluded. Thyroid disease requires TSH measurement, as hypothyroidism can cause anovulation. Hyperprolactinemia is evaluated with prolactin measurement, as prolactinoma can cause anovulation and amenorrhea. Non-classic congenital adrenal hyperplasia (21-hydroxylase deficiency) is screened with early-morning 17-hydroxyprogesterone; values above 200 ng/dL (6 nmol/L) warrant an ACTH stimulation test, with post-stimulation 17-OHP exceeding 1000 ng/dL confirming NCAH. The prevalence of NCAH is 1-10% of hyperandrogenic women depending on ethnicity, making this exclusion clinically important. Cushing syndrome should be screened for when clinical features are suggestive. An androgen-secreting tumor should be suspected with rapid-onset virilization, very high testosterone (above 150-200 ng/dL), or DHEA-S exceeding 700 mcg/dL. Acromegaly and hypothalamic amenorrhea complete the differential.

### Laboratory Assessment

The laboratory evaluation should include total and free testosterone (preferably calculated free testosterone via equilibrium dialysis or LC-MS/MS), SHBG (which is typically low in PCOS due to hyperinsulinemia), DHEA-S (mildly elevated in 20-30% of PCOS), 17-OHP (early morning, follicular phase for NCAH screening), TSH, and prolactin. Metabolic screening should include fasting glucose and insulin or a 2-hour 75g oral glucose tolerance test, with the OGTT preferred because 30-40% of obese women with PCOS have impaired glucose tolerance and 10% develop type 2 diabetes by age 40. The lipid panel characteristically shows low HDL, high triglycerides, and elevated small dense LDL. AMH (elevated above 3.4 ng/mL supports PCOS diagnosis) and LH/FSH may also be considered.

### Metabolic Risk Assessment

Comprehensive metabolic risk assessment is integral to PCOS care. Screening for type 2 diabetes or prediabetes (OGTT or HbA1c at diagnosis, then every 1-3 years), dyslipidemia, and NAFLD/NASH (ALT measurement, with ultrasound if elevated) should be performed. Obstructive sleep apnea screening is warranted when symptoms are present, given the higher prevalence in PCOS. Blood pressure monitoring, screening for depression and anxiety (2-3 times increased prevalence), and endometrial assessment (transvaginal ultrasound if amenorrheic for more than 3 months without withdrawal bleed, with endometrial biopsy if thickness exceeds 7-10 mm or irregular bleeding occurs) complete the evaluation.

## Management

### Lifestyle Modification (First-Line for All)

Lifestyle modification is the cornerstone of PCOS management regardless of the specific therapeutic goals. Weight loss of just 5-10% significantly improves ovulatory function (restoring ovulation in up to 75% of women), insulin sensitivity, androgen levels, menstrual regularity, fertility, and metabolic parameters. No single diet has been proven superior; Mediterranean and low-glycemic index diets show modest benefits, but caloric deficit is the critical factor. Exercise of at least 150 minutes per week of moderate intensity improves insulin sensitivity independently of weight loss. Behavioral and psychological support addressing body image concerns, emotional eating, and depression is an important component.

### Menstrual Regulation and Endometrial Protection

Combined oral contraceptives (COCs) are first-line for menstrual irregularity and hyperandrogenism in women not seeking pregnancy. They suppress LH, reducing ovarian androgen production; increase SHBG, lowering free testosterone; and provide regular endometrial shedding, preventing endometrial hyperplasia. Anti-androgenic progestins are preferred, including drospirenone, cyproterone acetate (not available in the US as a COC), norgestimate, and desogestrel. The lowest effective estrogen dose (20-35 mcg ethinyl estradiol) should be used, with awareness of VTE risk, particularly in women with obesity or age above 35.

Cyclic progestin (medroxyprogesterone acetate 10 mg daily for 10-14 days per month) induces withdrawal bleeding and provides endometrial protection but does not address hyperandrogenism; it is an option for women with contraindications to estrogen. A progestin-containing IUD (levonorgestrel IUD) provides excellent endometrial protection and may reduce menstrual bleeding but does not address systemic hyperandrogenism.

### Treatment of Hyperandrogenism

#### Hirsutism

COCs serve as first-line treatment, though full effect takes 6-9 months. Spironolactone at 50-200 mg/day provides additional anti-androgen benefit through androgen receptor blockade and 5-alpha-reductase inhibition. Reliable contraception is required because spironolactone can feminize a male fetus, and menstrual irregularity (mitigated by concurrent COC prescription) and hyperkalemia are potential side effects. Finasteride, a 5-alpha-reductase inhibitor at 5 mg daily, blocks conversion of testosterone to DHT and is used off-label for hirsutism, though it is category X for teratogenicity. Flutamide, a non-steroidal anti-androgen at 250 mg daily, is effective but limited by hepatotoxicity risk. Eflornithine cream 13.9% (Vaniqa), a topical agent that inhibits ornithine decarboxylase, slows facial hair growth but does not remove existing hair and is used as an adjunct. Mechanical hair removal through laser therapy (most effective for dark hair on light skin), electrolysis (permanent, effective for any hair type), shaving, and waxing provides important adjunctive treatment.

#### Acne

COCs and spironolactone address the hormonal component, supplemented by topical retinoids, benzoyl peroxide, and topical or oral antibiotics per dermatology guidelines. Isotretinoin is reserved for severe or refractory cases, with mandatory pregnancy prevention.

#### Androgenic Alopecia

Spironolactone, finasteride (off-label), topical minoxidil 2-5%, and COCs are used for treatment, though response is typically slower than for hirsutism.

### Insulin Sensitizers

Metformin at 1500-2000 mg/day (extended-release for gastrointestinal tolerance) improves insulin sensitivity, reduces androgens, and may restore ovulatory cycles in some women. Current ADA/ESHRE 2023 guidelines recommend metformin for metabolic indications (glucose intolerance/type 2 diabetes prevention) and as second-line for menstrual irregularity when COCs are not tolerated. It is less effective than COCs for hirsutism and acne. Although not FDA-approved for PCOS, it is widely used off-label.

Inositol (myo-inositol plus D-chiro-inositol at 2-4 g myo-inositol daily) functions as an insulin sensitizer with growing evidence for both metabolic and reproductive benefits. It is well-tolerated and considered by international guidelines as adjunctive therapy.

GLP-1 receptor agonists and tirzepatide are generating considerable excitement as emerging therapies for PCOS with obesity. Liraglutide 3 mg and semaglutide 2.4 mg have been studied in PCOS populations, showing significant weight loss and metabolic improvement. While not yet FDA-approved specifically for PCOS, they are used off-label for weight management and address insulin resistance, weight, and potentially ovulatory function.

### Fertility Treatment

| Agent | Dose | Mechanism | Ovulation Rate | Live Birth Rate | Line of Therapy | Key Notes |
|---|---|---|---|---|---|---|
| Letrozole | 2.5-7.5 mg daily, cycle days 3-7 | Aromatase inhibitor → ↑ FSH | ~62% | 27.5% (PPCOS II) | First-line | Superior to clomiphene; now standard of care |
| Clomiphene citrate | 50-150 mg daily, cycle days 5-9 | SERM → ↑ FSH | 70-80% | 19.1% (PPCOS II) | Second-line | Anti-estrogenic cervical mucus effects |
| Gonadotropins (FSH ± LH) | Low-dose step-up protocol | Direct follicular stimulation | >80% | Variable | Second-line (after oral agents fail) | High OHSS risk in PCOS; requires monitoring |
| Metformin (adjunct) | 1500-2000 mg daily | Insulin sensitizer → improves ovulation | 30-50% (lower than above) | Lower | Adjunctive | Best for metabolic benefits; additive with letrozole |

Letrozole, an aromatase inhibitor at 2.5-7.5 mg daily on cycle days 3-7, has replaced clomiphene as first-line ovulation induction for PCOS infertility. By blocking estrogen production, it releases FSH from estrogen-mediated suppression, promoting follicular development. The PPCOS II trial demonstrated significantly higher ovulation and live birth rates compared with clomiphene (27.5% vs 19.1% cumulative live birth rate). Clomiphene citrate, a SERM at 50-150 mg daily on cycle days 5-9, achieves ovulation in 70-80% and pregnancy in 30-40% but is now considered second-line. Gonadotropins (FSH with or without LH) are second-line when oral agents fail, employing a low-dose step-up protocol to minimize ovarian hyperstimulation syndrome (OHSS) risk, with monitoring by ultrasound and estradiol levels. Ovarian drilling (laparoscopic electrocautery or laser to the ovarian surface) is seldom used in the modern era. In vitro fertilization (IVF) is reserved for refractory anovulation or coexisting infertility factors, with GnRH antagonist protocols and agonist trigger preferred to reduce the heightened OHSS risk in PCOS. Weight loss before fertility treatment, even just 5%, significantly improves ovulation and pregnancy rates.

<image>A treatment algorithm for PCOS based on patient goals. Start with confirmed PCOS diagnosis. First branch: Patient goals. Branch 1 - Not seeking pregnancy: (a) If menstrual irregularity + hyperandrogenism → COC (anti-androgenic progestin) + spironolactone for hirsutism. (b) If metabolic risk → lifestyle modification ± metformin, consider GLP-1 RA for obesity. (c) Endometrial protection if amenorrheic. Branch 2 - Seeking pregnancy: (a) Lifestyle/weight optimization → letrozole first-line for ovulation induction → if fails, clomiphene → if fails, gonadotropins (low-dose step-up) → if fails, IVF. (b) Metformin as adjunct for metabolic benefits and ovulation support. Cross-cutting themes: lifestyle modification for all, screen for T2D/dyslipidemia/NAFLD, mental health assessment. Use flowchart with patient-centered decision nodes.</image>

## Long-Term Health Risks

### Metabolic

The metabolic consequences of PCOS are substantial and progressive. Type 2 diabetes risk is increased 5-8 fold, with up to 40% developing impaired glucose tolerance by age 40, making the OGTT the preferred screening tool. Metabolic syndrome affects 30-40% of women with PCOS. NAFLD/MASH prevalence reaches 30-60%, with increased risk of liver fibrosis. Cardiovascular risk factors, including dyslipidemia, hypertension, endothelial dysfunction, and increased carotid intima-media thickness, are prevalent, though whether PCOS represents an independent cardiovascular risk factor beyond these traditional risk factors remains debated.

### Reproductive

Endometrial hyperplasia and cancer risk is increased 2-6 fold, driven by chronic anovulation and resulting unopposed estrogen exposure. Endometrial surveillance and regular progestin exposure are protective. Pregnancy complications are increased, including gestational diabetes (2-3 fold), preeclampsia (2-3 fold), preterm birth, and cesarean delivery rates. Despite these challenges, many women with PCOS eventually conceive with or without treatment, and the elevated AMH levels characteristic of PCOS may actually extend the reproductive window.

### Psychological

Depression and anxiety are each 2-3 times more prevalent in PCOS, and eating disorders occur at increased rates. Decreased quality of life relating to body image concerns, hirsutism-related distress, and infertility stress affects many women. Addressing psychological well-being must be considered an integral component of comprehensive PCOS management.

## Key Clinical Pearls

- Letrozole has replaced clomiphene as first-line ovulation induction for PCOS infertility; the PPCOS II trial showed significantly higher live birth rates with letrozole (27.5% vs 19.1% with clomiphene)
- Non-classic congenital adrenal hyperplasia (21-hydroxylase deficiency) must be excluded in all women being evaluated for PCOS; a morning 17-OHP <200 ng/dL essentially excludes it; prevalence is 1-10% of hyperandrogenic women depending on ethnicity
- PCOS is fundamentally an insulin-resistant state in the majority of patients, including lean women; addressing insulin resistance (through weight loss, metformin, lifestyle) improves both metabolic and reproductive outcomes
- Endometrial cancer risk in PCOS is driven by chronic anovulation (unopposed estrogen); regular progestin exposure (via COC, cyclic progestin, or progestin IUD) is the primary preventive strategy
- GLP-1 receptor agonists (semaglutide, liraglutide) and tirzepatide are emerging as potentially transformative therapies for PCOS with obesity; they address weight, insulin resistance, and may improve reproductive function; formal PCOS indications are anticipated
- PCOS phenotype D (non-hyperandrogenic) has the mildest metabolic risk profile; phenotypes A and B (with hyperandrogenism) carry the highest metabolic and cardiovascular risk

## References

1. Teede HJ, et al. "International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome 2023." Monash University, 2023.
2. Legro RS, et al. "Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome (PPCOS II)." N Engl J Med. 2014;371(2):119-129.
3. Rosenfield RL, Ehrmann DA. "The Pathogenesis of Polycystic Ovary Syndrome (PCOS)." Endocr Rev. 2016;37(5):467-520.
4. Balen AH, et al. "The Management of Anovulatory Infertility in Women with Polycystic Ovary Syndrome: ESHRE/ASRM Guidelines." Hum Reprod. 2016;31(4):673-686.
5. Escobar-Morreale HF. "Polycystic Ovary Syndrome: Definition, Aetiology, Diagnosis and Treatment." Nat Rev Endocrinol. 2018;14(5):270-284.